DelveInsight’s Bladder cancer Pipeline Insight, 2023 report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Bladder cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Bladder cancer (BC) is the most common neoplasm of the urinary system. The wall of the bladder has several layers. Each layer is made up of different kinds of cells and Bladder cancer begins when healthy cells in the bladder lining—most commonly urothelial cells—change and grow out of control, forming a mass called a tumor. There are multiple known risk factors for Bladder cancer. Important risk factors include smoking, schistosomiasis infection, and occupational exposure to certain chemicals. Urothelial carcinoma is the most common histologic type of BC. Further, majority of newly diagnosed bladder cancers (75% to 80%) are classified as non-muscle invasive bladder cancer (NMIBC).
To know more about the Bladder Cancer pipeline report offerings @ Bladder Cancer Pipeline insight
Bladder Cancer Pipeline Analysis
The report provides insights into:
- The report provides detailed insights about companies that are developing therapies in the Bladder Cancer Market.
- It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Bladder Cancer treatment.
- Bladder Cancer key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Bladder Cancer Drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Bladder Cancer market.
To know more about the Bladder Cancer treatment landscape, click here to request for sample @ Bladder Cancer Therapies and Drugs
Emerging Bladder cancer Drugs
CG0070: CG Oncology
CG0070 is an investigational oncolytic immunotherapy based on a modified common cold adenovirus backbone that contains a cancer-specific promoter and a GM-CSF transgene. CG0070 was designed to work in two important and complementary ways. First, it replicates inside the tumor’s cells causing tumor cell lysis and immunogenic cell death. Then, the rupture of the cancer cells can release tumor-derived antigens, along with GM-CSF, that can stimulate a systemic anti-tumor immune response that involves the body’s own white blood cells. The scientific rationale and clinical profile of CG0070 make it an ideal agent to be developed for a variety of solid tumor types to be used alone or in combination with immune checkpoint modulators.
N-803: ImmunityBio
The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of the natural killer (NK) and T cells. N-803 is a novel IL-15 superagonist complex consisting of an IL-15 mutant (IL-15N72D) bound to an IL-15 receptor α/IgG1 Fc fusion protein. Its mechanism of action is direct specific stimulation of CD8+ T cells and NK cells through beta gamma T-cell receptor binding (not alpha) while avoiding T-reg stimulation.
UGN-102: UroGen
UroGen is developing UGN-102 (mitomycin) for intravesical solution as a primary nonsurgical alternative to repetitive TURBT. UGN-102 is an investigational formulation that utilizes our innovative technology, RTGel™ reverse-thermal hydrogel, for the treatment of low-grade NMIBC. Instilled via standard catheters, UGN-102 is designed to dwell for a period of several hours before being excreted via normal urine flow.
Trilaciclib: G1 Therapeutics
Trilaciclib, an IV-administered transient CDK4/6 inhibitor, is a first-in-class therapy designed to preserve bone marrow and immune system function during chemotherapy to improve patient outcomes. The company is currently enrolling patients in PRESERVE 3, Phase 2, randomized, open-label study of trilaciclib administered with first-line platinum-based chemotherapy and the immune checkpoint inhibitor avelumab maintenance therapy in patients with untreated, locally advanced or metastatic urothelial carcinoma (mUC). Myeloprotection and anti-tumor efficacy endpoints are being assessed in this study.
Request for sample to know more about recent Bladder Cancer developments, click here @ Bladder Cancer Clinical trials advancements
Types of Bladder cancer
There are different types of bladder cancer that begin in the lining of the bladder.
• Urothelial carcinoma (also called transitional cell carcinoma) is cancer that begins in the urothelial cells, which line the urethra, bladder, ureters, renal pelvis, and some other organs. Almost all bladder cancers are urothelial carcinomas.
• Squamous cell carcinoma is cancer that begins in squamous cells (thin, flat cells lining the inside of the bladder). This type of cancer may form after long-term irritation or infection with a tropical parasite called schistosomiasis.
• Adenocarcinoma is cancer that begins in glandular cells that are found in the lining of the bladder. Glandular cells in the bladder make mucus and other substances.
• Small cell carcinoma of the bladder is cancer that begins in neuroendocrine cells (nerve-like cells that release hormones into the blood in response to a signal from the nervous system).
Key companies in the Bladder Cancer Market are:
Some of the Bladder Cancer companies working in the market are CG Oncology, FKD Therapies, Bristol-Myers Squibb, LintonPharm Co., Ltd., ImmunityBio, Inc., Hamlet Pharma AB, Asieris Pharmaceuticals, Pfizer, Taizhou Hanzhong biomedical co. LTD, Protara Therapeutics, CicloMed LLC, enGene, Inc., Emtora Biosciences, Theralase Inc., Vaxiion Therapeutics, Janssen Research & Development, LLC, Astellas Pharma, RemeGen Co., Ltd., UroGen Pharma Ltd., Flame Biosciences, Aura Biosciences, BeiGene, Incyte Corporation, QED Therapeutics, G1 Therapeutics, AN0025, Kyowa Kirin, Inc., Infinity Pharmaceuticals, Shanghai Hengrui Pharmaceutical Co., Ltd., HiberCell, Inc., Ikena Oncology, Genentech, Fusion Pharmaceuticals, GI Innovation,SOTIO Biotech AG, Celon Pharma SA, 4D Pharma PLC, Keythera Pharmaceuticals, Quadriga Biosciences, Inc., NeoTX Therapeutics Ltd., Mirati Therapeutics, NGM Biopharmaceuticals, TransThera Biosciences, Ocellaris Pharma, Palleon Pharmaceuticals, Medicenna Therapeutics, Klus Pharma, Novartis, Toray Industries, Carisma Therapeutics, Avacta Life Sciences Ltd, Seagen Inc., Elevation Oncology, Corvus Pharmaceuticals, ADC Therapeutics S.A., IO Biotech, Byondis B.V., Takara Bio, Seven and Eight Biopharmaceuticals, Dragonfly Therapeutics, InnoCare Pharma, and others
Bladder Cancer Therapies covered in the report include:
- CG0070: CG Oncology
- N-803: ImmunityBio
- UGN-102: UroGen
- Trilaciclib: G1 Therapeutics
- And many more
Request the Sample PDF to Get a more in-depth Bladder Cancer Pipeline Assessment: https://www.delveinsight.com/sample-request/bladder-cancer-pipeline-insight
Table of Content
1. Report Introduction
2. Executive Summary
3. Bladder Cancer Current Treatment Patterns
4. Bladder Cancer - DelveInsight's Analytical Perspective
5. Bladder cancer Therapeutic Assessment
6. Bladder Cancer Late Stage Products (Phase-III)
7. Bladder Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Bladder cancer Products
11. Dormant Bladder cancer Products
12. Bladder Cancer Discontinued Products
13. Bladder Cancer Product Profiles
14. Bladder Cancer Key Companies
15. Bladder Cancer Key Products
16. Dormant and Discontinued Products
17. Bladder Cancer Unmet Needs
18. Bladder Cancer Future Perspectives
19. Bladder Cancer Analyst Review
20. Appendix
21. Report Methodology
*The table of contents is not exhaustive; the final content may vary.
Request for the Sample PDF (to get a detailed understanding of the Bladder Cancer pipeline therapies included in the report), at: Bladder Cancer Therapeutic Assessment
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services
